Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Boji Medical Sells Fluconazole Ear Drops Technology to Chengdu Pusch for $2M

Fineline Cube Apr 22, 2026
Company Deals

Novabio Therapeutics and OBiO Tech Strengthen Partnership to Advance Treg Cell Therapies for Neurodegenerative Diseases

Fineline Cube Apr 22, 2026
Company Deals

InxMed Limited Files for Hong Kong IPO with Near-Commercial FAK Inhibitor Ifebemtinib

Fineline Cube Apr 22, 2026
Company Deals

NeuroGen Pharma Secures Exclusive China Rights to Teva’s Ajovy – World’s First Dual-Indication CGRP Antagonist for Migraine Prevention

Fineline Cube Apr 22, 2026
Company Deals

Eli Lilly to Acquire Kelonia Therapeutics for $7 Billion to Secure In Vivo CAR-T Platform Targeting Multiple Myeloma

Fineline Cube Apr 21, 2026
Policy / Regulatory

China Tightens Control Over Pregabalin and Dextromethorphan-Guaifenesin Preparations Amid Abuse Concerns; NMPA, Police, and Narcotics Agency Issue Joint Enforcement Directive

Fineline Cube Apr 21, 2026
Company Drug

Merck’s Idvynso Gains FDA Approval as Novel Dual-Drug HIV Treatment

Fineline Cube Apr 22, 2026
Company Drug

Roche’s Fenebrutinib Slashes MS Relapse Rates by Over 50% in Phase III Trials

Fineline Cube Apr 22, 2026
Company Deals

Kunshi Biotechnology and Puheng Technology Partner on 3D NAC-Organ Platform for CAR-Macrophage Screening

Fineline Cube Nov 23, 2022

Kunshi Biotechnology (Shenzhen) Co., Ltd and Suzhou Puheng Technology Co., Ltd have entered into a...

Company Deals Medical Device

Endoso Life Raises Pre-Series A Funding for High-End Medical Endoscope Development

Fineline Cube Nov 23, 2022

Endoso Life, a Hangzhou-based developer of high-end medical endoscope systems and devices, has reportedly raised...

Company Drug

Vcanbio’s VUM02 Accepted for Review by China’s Center for Drug Evaluation

Fineline Cube Nov 23, 2022

China-based Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that the clinical...

Company Drug

Fosun Pharma’s Human Interferon Gamma Approved for New Indication by NMPA

Fineline Cube Nov 23, 2022

Shanghai Fosun Pharmaceutical Group Co (SHA: 600196) has announced receiving another indication approval from the...

Company Drug

InnoCare Pharma’s Hibruka Receives HSA Approval for Mantle Cell Lymphoma in Singapore

Fineline Cube Nov 23, 2022

China-based InnoCare Pharma (HKG: 9969, SHA: 688428) has announced receiving market approval from the Health...

Company Deals

Sun-Novo Pharma to Acquire MAH Rights for Azilsartan from Baiao Pharma

Fineline Cube Nov 23, 2022

China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced plans to acquire the...

Company Deals

UB Biotechnology Secures Series A Funding for Flow Cytometry Platform

Fineline Cube Nov 22, 2022

China-based in vitro diagnostics (IVD) maker UB Biotechnology (Zhejiang) Co., Ltd has reportedly raised “tens...

Company Deals

IASO Biotherapeutics Partners with Umoja Biopharma to Evaluate iCIL Platform

Fineline Cube Nov 22, 2022

China-based biopharma IASO Biotherapeutics has announced a research agreement with US immuno-oncology company Umoja Biopharma,...

Policy / Regulatory

Shanghai Unveils Policies to Boost Global Biomedical R&D Hub

Fineline Cube Nov 22, 2022

The Shanghai municipal government has released a set of policies and measures aimed at accelerating...

Company

WuXi Biologics Launches Integrated Biologics CRDMO Center in Shanghai

Fineline Cube Nov 22, 2022

China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has launched its...

Company Deals

Nona Biosciences Licenses HCAb Technology to Dragonfly Therapeutics

Fineline Cube Nov 22, 2022

Nona Biosciences, a newly established wholly owned subsidiary of Harbour BioMed (HKG: 2142), has struck...

Company Drug

Salubris Pharmaceuticals’ SAL0119 Accepted for CDE Review in China

Fineline Cube Nov 22, 2022

China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) has announced that its clinical trial filing...

Company Drug

Aosaikang’s ASKG915 Accepted for FDA Review, Targets Advanced Solid Tumors

Fineline Cube Nov 22, 2022

Beijing Aosaikang Pharmaceutical Co., Ltd (SHE: 002755) has announced that its clinical trial filing for...

Company Drug

Legend Biotech Receives IND Approval for LB2102 CAR-T Therapy

Fineline Cube Nov 22, 2022

China-based Legend Biotech Corporation (NASDAQ: LEGN) has announced receiving Investigational New Drug (IND) approval for...

Company Drug

Sun-Novo Pharma Gains NMPA Approval for STC007 Clinical Study in CKD-aP

Fineline Cube Nov 22, 2022

China-based Beijing Sun-Novo Pharmaceutical Research Co., Ltd (SHA: 688621) has announced receiving approval from the...

Company Deals

JD Healthcare Partners with Jiangsu Yuyue for Medical Device Collaboration

Fineline Cube Nov 22, 2022

JD Healthcare, a unit of China’s e-commerce giant JD.com (NASDAQ: JD), has announced a partnership...

Company Drug

Junshi Biosciences’ JunMaiKang Approved by NMPA for Multiple Indications

Fineline Cube Nov 22, 2022

China-based Junshi Biosciences (HKG: 1877, SHA: 688180) has announced that its JunMaiKang, a biosimilar version...

Company Drug

Hengrui Pharmaceuticals Receives FDA ANDA Approval for Gadobutrol Generic

Fineline Cube Nov 22, 2022

China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced receiving Abbreviated New Drug Application (ANDA) status...

Company Drug

Fosun Pharma’s Bivalent COVID-19 Vaccine Comirnaty Authorized in Hong Kong

Fineline Cube Nov 21, 2022

Shanghai Fosun Pharmaceutical Group Co (SHA: 600196) has announced obtaining emergency use authorization (EUA) in...

Company Drug

IASO Biotherapeutics Reports Positive Phase I Results for CAR-T Therapy in NMOSD

Fineline Cube Nov 21, 2022

China-based IASO Biotherapeutics has announced the interim results of a Phase I investigator-initiated-trial (ITT) for...

Posts pagination

1 … 586 587 588 … 655

Recent updates

  • Merck’s Idvynso Gains FDA Approval as Novel Dual-Drug HIV Treatment
  • Boji Medical Sells Fluconazole Ear Drops Technology to Chengdu Pusch for $2M
  • Roche’s Fenebrutinib Slashes MS Relapse Rates by Over 50% in Phase III Trials
  • Novabio Therapeutics and OBiO Tech Strengthen Partnership to Advance Treg Cell Therapies for Neurodegenerative Diseases
  • Gan & Lee’s Nectin-4 ADC GLR1059 Clears Regulatory Hurdle for Solid Tumor Trials
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Merck’s Idvynso Gains FDA Approval as Novel Dual-Drug HIV Treatment

Company Deals

Boji Medical Sells Fluconazole Ear Drops Technology to Chengdu Pusch for $2M

Company Drug

Roche’s Fenebrutinib Slashes MS Relapse Rates by Over 50% in Phase III Trials

Company Deals

Novabio Therapeutics and OBiO Tech Strengthen Partnership to Advance Treg Cell Therapies for Neurodegenerative Diseases

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.